chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the Healthcare professional reiterates that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment with the State at this time. It was reported that no adverse reactions were reported by any patients. No treatment medication was provided.
Joint affected in left groin/hip area.  Cannot put weight on left foot.  Difficulty walking or standing.   Using cane to take pressure off left foot.
Aching neck and upper back shoulders, lack of energy (~6PM).   Chills and low grade fever sore injection site (~1AM).  Sore injection site and lack of energy (following morning).
Injection site itching; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Injection site itching) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. L016M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Injection site itching). At the time of the report, VACCINATION SITE PRURITUS (Injection site itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication information was not provided. Treatment information was not provided.
Arm is hurting; "Itches like crazy"; rash at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Arm is hurting), PRURITUS ("Itches like crazy") and VACCINATION SITE RASH (rash at injection site) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced VACCINATION SITE PAIN (Arm is hurting), PRURITUS ("Itches like crazy") and VACCINATION SITE RASH (rash at injection site). At the time of the report, VACCINATION SITE PAIN (Arm is hurting), PRURITUS ("Itches like crazy") and VACCINATION SITE RASH (rash at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. Treatment information not provided.
Approximately a week after booster, I developed arthralgias in hands, wrist, elbows in a migratory pattern. They also affected my shoulders and knees only mildly. About 2 months into the symptom development, I was unable to open a doorknob and pain kept me awake at night and I was having difficulty at work performing duties. I was unable to cook, unable to dress, unable to go to the gym.   The arthralgias intensified over several weeks to the point I began to believe this may be the onset of a new chronic illness and so I sought the help of my PCP who referred me to rheumatologist. Rheum believes this may related to the Covid booster I received. The symptoms are now much less severe. It is 5-11-22 and pain is almost completely gone, I am no longer on Motrin or any heat and back to the gym. I was very worried about the symptoms when they first appeared and had no idea a booster could potentially cause that. I had no joint issues with the first 2 shots or the covid19 virus.  I did have Covid-19 in November and developed covid pneumonia for which i was treated with antibiotics-but no covid related issues at time of vaccine which was over a month and a half after i had covid.
I had terrible night sleeping. I couldn't get warm. It was a miserable night. I woke up and I was in a lot of pain doing my normal calisthenics. It was like I did a super workout. It was like every joint hurt. It progressively got worse during the day. I had cough and I measured my temperature at 99 degrees. I did it again and it reached 100 degrees, eventually it reached 100.3 degrees. I was scheduled for a procedure for my eye, and I did a home COVID-19 test and it showed two bars. I said yep, I got COVID-19. I heard about the antiviral pill, Paxlovid, so I got in touch with my Primary doctor, and I asked about getting it and he suggested that I go get it. I have been on it; I have three doses left.
L thigh, red, itchy rash 1 - 2 days after DTaP vaccine on 7/12/17. Getting bigger today. + itchy, no pain. Nowhere else. Never before.
Respiratory infection in sinus/chest and ear; Body ached; Chills; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (Respiratory infection in sinus/chest and ear), PAIN (Body ached) and CHILLS (Chills) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 02-Jun-2021, the patient experienced PAIN (Body ached) and CHILLS (Chills). On an unknown date, the patient experienced SINUSITIS (Respiratory infection in sinus/chest and ear). In June 2021, PAIN (Body ached) and CHILLS (Chills) had resolved. At the time of the report, SINUSITIS (Respiratory infection in sinus/chest and ear) had not resolved.   No concomitant medication information was reported. No treatment medication information was reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Patient developed fever and emesis on 5/23. Diarrhea started 5/24 and lasted 4 days total, 2 days and vomiting. "Extreme lethargy" for 7 days per parents. They did not bring him to our office for evaluation as requested by us on 5/27.
Rash noted yesterday over bilateral upper arm and bilateral thighs. No fever, no URI sx, no conjunctivitis.
Pt. reports having discomfort in her arm and shoulder since receiving her influenza vaccination 3 weeks ago. (Pt. encouraged to see physician).
Blood sugars are elevated; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE INCREASED (Blood sugars are elevated) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product PROCAINE HYDROCHLORIDE (NOVOCAINE) for an unknown indication.    Concurrent medical conditions included Diabetes mellitus (blood sugars are normally well-controlled).   On 28-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started PROCAINE HYDROCHLORIDE (NOVOCAINE) (unknown route) at an unspecified dose. On an unknown date, the patient experienced BLOOD GLUCOSE INCREASED (Blood sugars are elevated). At the time of the report, BLOOD GLUCOSE INCREASED (Blood sugars are elevated) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: elevated (High) elevated blood sugars.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.    Reporter did not allow further contact
Patient experienced pain and swelling at the injection site for 2 days, right deltoid. She also experienced numbness in her right hand for those 2 days. Pain and swelling began a couple of hours after the injection was given and persisted for 2 days and resolved spontaneously.
Very sore arm; Constant fever between 99 and 102 degrees; Constant headache; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11th November 2022, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 11th November 2022, 3 hrs after receiving Shingrix, the patient experienced pain in arm, fever and headache. On an unknown date, the outcome of the pain in arm, fever and headache were not recovered/not resolved.   It was unknown if the reporter considered the pain in arm, fever and headache to be related to Shingrix.     Additional Information: GSK Receipt Date: 14-NOV-2022 Reporter's comments: The reporter was the patient and had received her first Shingrix vaccine in the left arm. She had experienced  a very sore arm since the day she had received the Shingrix. She had a constant fever that was being fluctuated between 99 and 102 degrees Farhenit.  The reporter also had reported that she has had a constant headache, except for maybe two hours since receiving the vaccine. The reporter did not consent to follow up.
Approximately one hour after receiving Pfizer booster, patient developed one hive on left forearm measuring 1/2 inch with a 5 inch border of erythema.  Administered 25 mg Benedryl. One hour after administering the Benedryl, the erythema had disappeared and the hive had faded.  No further medications needed. Patient recovered.
patient was admitted for planned left atrial appendage closure device (watchman) placement due to high risk of bleeding secondary to falls and syncope while on anticoagulation for PAF. She had no complications post-operatively.  Discharged after 27 hours. Hospital admission within 6 weeks of receiving the COVID vaccine.
I previously had covid in August 2020. Felt fine until I went to bed. Woke up in the middle of the night with a fever of 101, HORRIBLE body aches and pains all over, headache, nausea. Felt 10 times worse than when I had Covid in August. Woke this morning to a few sharp pains in my left armpit. Fever has continued (101.2 at time of submission). Body aches continue, but at a lessened degree.
Moderna Covid-19 Vaccine EUA  Patient had low grade fever (101.1 degrees) as well as muscle aches and pain
Got on 9/9 dry throat, eyes bloodshot that night chills, headache, fast HR-started at 2pm-mild sx 2 yrs ago w/ flu shot. 9/10-still have sx but more mild.
she cannot move her arm as it hurts so bad; She is having a hard time concentrating; sensitive to light; no energy today; Her first dose injection site has turned red again and it looks like the rash is about to star; felt nauseous and dizzy; tingling in her neck, tingling went down to her hands; a taste in her mouth; felt nauseous and dizzy; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (tingling in her neck, tingling went down to her hands), TASTE DISORDER (a taste in her mouth), DIZZINESS (felt nauseous and dizzy), PAIN IN EXTREMITY (she cannot move her arm as it hurts so bad) and DISTURBANCE IN ATTENTION (She is having a hard time concentrating) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 011M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced PARAESTHESIA (tingling in her neck, tingling went down to her hands), TASTE DISORDER (a taste in her mouth), DIZZINESS (felt nauseous and dizzy) and NAUSEA (felt nauseous and dizzy). On 20-Feb-2021, the patient experienced PAIN IN EXTREMITY (she cannot move her arm as it hurts so bad), DISTURBANCE IN ATTENTION (She is having a hard time concentrating), PHOTOPHOBIA (sensitive to light), FATIGUE (no energy today) and ERYTHEMA (Her first dose injection site has turned red again and it looks like the rash is about to star). At the time of the report, PARAESTHESIA (tingling in her neck, tingling went down to her hands) had not resolved and TASTE DISORDER (a taste in her mouth), DIZZINESS (felt nauseous and dizzy), PAIN IN EXTREMITY (she cannot move her arm as it hurts so bad), DISTURBANCE IN ATTENTION (She is having a hard time concentrating), PHOTOPHOBIA (sensitive to light), FATIGUE (no energy today), ERYTHEMA (Her first dose injection site has turned red again and it looks like the rash is about to star) and NAUSEA (felt nauseous and dizzy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.9 (Low) low grade fever about 99.9.         patient take some ibuprofen (for her back and knee pain) but has not taking any Ibuprofen for the second dose and taken Benadryl post vaccination of both doses.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
On-set on dizziness, severe pain and swelling in left arm. 6 hour later, severe pain shooting up my arm, radiating up my neck to my left ear. Severe pain on left side of chest, left breast and pain radiating over shoulder to back on left side. On scale of 1-10, the pain was a 9. Extreme heaviness on both sides of chest. I could breath but seemed difficult to take deep breaths. Took an extra dose of my blood pressure meds and it eased the pain to a 4-5 and I was finally able to sleep at 1:00 AM.  Starting on March 8, 2021 I began having severe night sweats and continue to have them at present (March 25, 2021). Dr does not recommend that I take the second vaccination due to my reaction to the first one. He did recommend that I take the Johnson & Johnson but the health department is stating that I have to complete my vaccinations with the same on I started with. I will not have the second Pfizer.
Fever; Flu-like symptoms; Headache; cough and nasal congestion; cough and nasal congestion; This case was reported by a nurse via call center representative and described the occurrence of fever in a 18-year-old male patient who received Men B NVS (Bexsero) (batch number ABX769AA, expiry date 31st July 2020) for prophylaxis.   On 12th June 2019, the patient received the 1st dose of Bexsero (intramuscular). On 12th June 2019, less than a day after receiving Bexsero, the patient experienced fever, influenza-like symptoms, headache, cough and nasal congestion. On an unknown date, the outcome of the fever, influenza-like symptoms, headache, cough and nasal congestion were recovered/resolved.   It was unknown if the reporter considered the fever, influenza-like symptoms, headache, cough and nasal congestion to be related to Bexsero.  Additional details were provided as follows: The patient experienced flu-like symptoms which were described as cough and nasal congestion.
She has not experienced any side effects other than muscle pain; administered punctured the needle at an angle which resulted to tearing the skin and having the vaccine leak out; vaccine leaking from the needle as well; This is a spontaneous report from a Pfizer-sponsored program (CEP/PSP: 159558). A contactable consumer (patient) reported that, an 89-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: not reported), dose 2 via an unspecified route of administration on 12Feb2021 as a DOSE 2, SINGLE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: not reported), dose 2 via an unspecified route of administration on an unspecified date as a DOSE 1, SINGLE for covid-19 immunisation. After first dose, she was feeling exhausted for two days and her muscles were sore. On 12Feb2021, the patient administered punctured the needle at an angle which resulted to tearing the skin and having the vaccine leak out and vaccine was leaking from the needle as well. She had muscle pain on an unspecified date. Reporter wanted to ask if she should be revaccinated as the person who gave her the 2nd dose of the vaccine on 12Feb2021 at a parking lot administered punctured the needle at an angle which resulted to tearing the skin and having the vaccine leak out. Reporter mentioned that there was also vaccine leaking from the needle as well. She was concerned that an incomplete dose was given to her. She had not experienced any side effects other than muscle pain. She mentioned that her doctor has patients with similar problems and referred her to Pfizer. Reporter had received both vaccines now. 2nd dose on 12Feb. Needle was inserted at an angle and reported that it hurt badly. When needle removed, she tore skin and brown liquid leaked out. Had no side effects like she did after first dose which were feeling exhausted for two days and her muscles were sore. Reporter was wondering if she should get vaccinated a third time. Outcome of the event was unknown.  Information about lot/batch number has been requested.  Follow-up (14May2021): Follow-up attempts completed. No further information expected.
Extreme heartburn; sinus pressure with headache; sinus pressure with headache; body aches; loose bowels; fatigue.; This is a spontaneous report from a Non-contactable consumer. This consumer reported for male patient that a 45-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on 11Mar2021 (at the age of 45 years old) as single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection) for covid-19 immunisation. The patient did not receive any other vaccines within four weeks. It was unknown that the patient had covid prior vaccination. It was unknown that the patient had tested for COVID-19 since having the vaccine. On 11Mar2021, patient experienced extreme heartburn, sinus pressure with headache, body aches, loose bowels, fatigue. It was unknown that the patient had received any treatment for events. The outcome of events was recovered on an unspecified date in Mar2021.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
PT had influenza injection in deltoid.  C/o deep muscle pain to wrist X 2-3 weeks.   Took OTC ALLEVE sporadically.  Concerned re: nerve damage or staph infection pending.
disseminated HSV1, symptoms started 8/17 with fever, HA.  Developed CP, dysphagia, oral ulcers, dysuria.   ER visits x 2 for symptom management, dehydration. Endoscopy with biopsy on 8/23/2021.  Confirmed HSV1- started Acyclovir on 8/26/2021
This case was reported by a consumer via sales rep and described the occurrence of fever in a patient who received SHINGRIX for prophylaxis. On 4th April 2019, the patient received SHINGRIX. On 4th April 2019, less than a day after receiving SHINGRIX, the patient experienced fever, chills, pain, injection site rash, rash and sickness. On an unknown date, the outcome of the fever and chills were recovered/resolved and the outcome of the pain, injection site rash, rash and sickness were unknown. It was unknown if the reporter considered the fever, chills, pain, injection site rash, rash and sickness to be related to SHINGRIX. Additional details were provided as follows: On 4th and 5th April 2019 (Thursday and Friday), the patient had fever of 101 degree F, chills, aches and rash at injection site. On 7th April 2019 (Sunday), the rash spread to entire upper arm and was just keep spreading. Till the time of reporting, the patient was still sick.
The patient developed a fever, was hospitalized at an unspecified hospital for an unspecified length of time; The patient "eventually died" on an unspecified date several years ago. Cause of death: unknown; This spontaneous report was received from the pharmacist via a company representative, referring to a 16-year-old female patient. The patient's current conditions, medical history, concomitant medications, drug reactions or allergies were not reported.   On an unknown date (reported as "several years ago"), the patient received unidentified Merck hpv vaccine administered (name and lot for prophylaxis (dose, strength, lot# and expiration date were not reported) or HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) as prophylaxis (dose, strength, lot# and expiration date were not reported). The patient was vaccinated at the clinic of an unspecified physician, not at a pharmacy.   On an unspecified date (reported as "several years ago"), the patient developed a fever, was hospitalized at an unspecified hospital for an unspecified length of time and received an unknown type of treatment. On an unknown date, the patient eventually died from an unknown cause. It was unknown if an autopsy was performed.   At the time of this report, the causality assessment between the unidentified Merck hpv vaccine administered (name and lot number not provided) and the events, were not reported. The reporter considered the event of fever to be life threatening.